TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$282 Million

Morphic Holding, Inc.

Follow-on Offering

Bookrunner, March 2021

Morphic Holding, Inc.

Morphic Holding, Inc. is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages Morphic’s unique understanding of integrin structure and biology.